New drug aims to shield lung cancer patients from Chemo's bone marrow side effects
NCT ID NCT06370416
First seen Feb 01, 2026 · Last updated Apr 29, 2026 · Updated 12 times
Summary
This study tests whether giving trilaciclib before chemotherapy can prevent severe drops in white blood cells, red blood cells, and platelets in people with advanced non-small cell lung cancer. About 41 participants will receive the drug before each chemo session. The goal is to reduce infections, anemia, and bleeding risks caused by bone marrow suppression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Henan Tumor Hospital
Zhengzhou, Henan, 450000, China
Conditions
Explore the condition pages connected to this study.